Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma - Publication - Bridge of Knowledge

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Abstract

Citations

1 0

CrossRef
0

Web of Science
1 1

Scopus

Authors (17)

Luca Arcaini
Thierry Lamy
Jan Walewski
David Belada
Jiri Mayer
John Radford
Wojciech Jurczak MD, PhD, Prof
Franck Morschhauser
Julia Alexeeva
Simon Rule
José Cabeçadas
Elias Campo
Stefano Pileri
Tsvetan Biyukov
Meera Patturajan
Marie-Laure Casadebaig
Marek Trnĕný

Cite as

Full text

full text is not available in portal

full content of the article see on external site open in new tab

Details

Category:: Magazine publication
Type:: Magazine publication
Published in:: BRITISH JOURNAL OF HAEMATOLOGY no. 180, edition 2, pages 224 - 235,
ISSN: 0007-1048
ISSN:: 0007-1048
Publication year:: 2018
DOI:: Digital Object Identifier (open in new tab) 10.1111/bjh.15025
Verified by:: No verification

seen 76 times